These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27749844)

  • 1. Prospective functional classification of all possible missense variants in PPARG.
    Majithia AR; Tsuda B; Agostini M; Gnanapradeepan K; Rice R; Peloso G; Patel KA; Zhang X; Broekema MF; Patterson N; Duby M; Sharpe T; Kalkhoven E; Rosen ED; Barroso I; Ellard S; ; Kathiresan S; ; O'Rahilly S; ; Chatterjee K; Florez JC; Mikkelsen T; Savage DB; Altshuler D
    Nat Genet; 2016 Dec; 48(12):1570-1575. PubMed ID: 27749844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.
    Majithia AR; Flannick J; Shahinian P; Guo M; Bray MA; Fontanillas P; Gabriel SB; ; ; ; ; Rosen ED; Altshuler D
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13127-32. PubMed ID: 25157153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacogenetic Approach to the Treatment of Patients With
    Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
    Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
    Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
    Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ mutations, lipodystrophy and diabetes.
    Astapova O; Leff T
    Horm Mol Biol Clin Investig; 2014 Nov; 20(2):63-70. PubMed ID: 25460295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics and Clinical Characteristics of PPARγ Variant-Induced Diabetes in a Chinese Han Population.
    Gong S; Han X; Li M; Cai X; Liu W; Luo Y; Zhang SM; Zhou L; Ma Y; Huang X; Li Y; Zhou X; Zhu Y; Wang Q; Chen L; Ren Q; Zhang P; Ji L
    Front Endocrinol (Lausanne); 2021; 12():677130. PubMed ID: 34764936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes.
    Doney ASF; Fischer B; Cecil JE; Boylan K; McGuigan FE; Ralston SH; Morris AD; Palmer CNA
    Diabetologia; 2004 Mar; 47(3):555-558. PubMed ID: 14730381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic PPARγ deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility.
    Gilardi F; Winkler C; Quignodon L; Diserens JG; Toffoli B; Schiffrin M; Sardella C; Preitner F; Desvergne B
    Metabolism; 2019 Jun; 95():8-20. PubMed ID: 30878493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population.
    Ho JS; Germer S; Tam CH; So WY; Martin M; Ma RC; Chan JC; Ng MC
    Diabetes Res Clin Pract; 2012 Sep; 97(3):483-91. PubMed ID: 22515931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes.
    Hansen SK; Nielsen EM; Ek J; Andersen G; Glümer C; Carstensen B; Mouritzen P; Drivsholm T; Borch-Johnsen K; Jørgensen T; Hansen T; Pedersen O
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3629-37. PubMed ID: 15797964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid metabolism in patients with PPARgamma mutations.
    Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women.
    Chan KH; Niu T; Ma Y; You NC; Song Y; Sobel EM; Hsu YH; Balasubramanian R; Qiao Y; Tinker L; Liu S
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E600-4. PubMed ID: 23386649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study.
    Doney AS; Fischer B; Leese G; Morris AD; Palmer CN
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2403-7. PubMed ID: 15486307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unsupervised Clustering of Missense Variants in HNF1A Using Multidimensional Functional Data Aids Clinical Interpretation.
    Althari S; Najmi LA; Bennett AJ; Aukrust I; Rundle JK; Colclough K; Molnes J; Kaci A; Nawaz S; van der Lugt T; Hassanali N; Mahajan A; Molven A; Ellard S; McCarthy MI; Bjørkhaug L; Njølstad PR; Gloyn AL
    Am J Hum Genet; 2020 Oct; 107(4):670-682. PubMed ID: 32910913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
    Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
    Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
    Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
    Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance evaluation of pathogenicity-computation methods for missense variants.
    Li J; Zhao T; Zhang Y; Zhang K; Shi L; Chen Y; Wang X; Sun Z
    Nucleic Acids Res; 2018 Sep; 46(15):7793-7804. PubMed ID: 30060008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
    Broekema MF; Massink MPG; Donato C; de Ligt J; Schaarschmidt J; Borgman A; Schooneman MG; Melchers D; Gerding MN; Houtman R; Bonvin AMJJ; Majithia AR; Monajemi H; van Haaften GW; Soeters MR; Kalkhoven E
    Mol Metab; 2019 Feb; 20():115-127. PubMed ID: 30595551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.